Researchers tackle the product-agnostic problems that plague pain drug research
When it comes to what matters most to patients, the alleviation of pain is often top of the list. But designing clinical trials for new analgesics has proven particularly troublesome, writes IMI Executive Director Pierre Meulien in this opinion piece.
IMI – radical collaboration in action
A new brochure, 'IMI - radical collaboration in action', showcases some recent IMI project successes, which include an approved vaccine for Ebola, insights into the genetics of Alzheimer’s disease, a new classification of diabetes, and advances on using liquid biopsies for cancer, as well as contributions to the fight against COVID-19.
IMI covid-19 response
Within weeks of the first reports of coronavirus in Europe, IMI launched a fast-track Call for proposals to develop therapeutics and diagnostics for current and future coronavirus outbreaks